Contineum Therapeutics (CTNM) Expected to Announce Quarterly Earnings on Wednesday

Contineum Therapeutics (NASDAQ:CTNM) is expected to be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Contineum Therapeutics Trading Up 6.8 %

Shares of CTNM opened at $7.91 on Friday. The company’s fifty day moving average is $11.79 and its two-hundred day moving average is $15.27. Contineum Therapeutics has a fifty-two week low of $7.04 and a fifty-two week high of $22.00.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 target price on shares of Contineum Therapeutics in a research report on Thursday, January 9th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $29.25.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).